Phase II study of linifanib in KRAS mutated metastatic refractory colorectal cancer

被引：0
|
作者：
Chan, E. [1 ]
Ayers, G. D. [2 ]
Goff, L. [1 ]
McClanahan, P. [3 ]
Holloway, M. [3 ]
Ciombor, K. [1 ]
Smith, S. J. [1 ]
Ancell, K. [1 ]
Cardin, D. B. [1 ]
Berlin, J. [1 ]
机构：
[1] Vanderbilt Univ, Med Ctr, Div Med Oncol, Nashville, TN USA
[2] Vanderbilt Univ, Med Ctr, Ctr Quantitat Sci, Nashville, TN USA
[3] Vanderbilt Univ, Med Ctr, Nashville, TN USA
来源：
EUROPEAN JOURNAL OF CANCER | 2013年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2369
引用
收藏
页码：S549 / S549
页数：1
相关论文
共 50 条
  • [21] Phase II Study of Panitumumab With Irinotecan for Patients With KRas Wild-type Metastatic Colorectal Cancer (MCRC) Refractory to Standard Chemotherapy - a GERCor Study
    Andre, T.
    Chibaudel, B.
    Mabro, M.
    Bennamoun, M.
    Artru, P.
    Bachet, J. B.
    Hadengue, A.
    Blons, H.
    Laurent-Puig, P.
    de Gramont, A.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S435 - S435
  • [22] Randomized Phase II Open-Label Study of mFOLFOX6 in Combination With Linifanib or Bevacizumab for Metastatic Colorectal Cancer
    O'Neil, Bert H.
    Cainap, Calin
    Van Cutsem, Eric
    Gorbunova, Vera
    Karapetis, Christos S.
    Berlin, Jordan
    Goldberg, Richard M.
    Qin, Qin
    Qian, Jiang
    Ricker, Justin L.
    Fischer, JuDee
    McKee, Mark D.
    Carlson, Dawn M.
    Kim, Tae Won
    CLINICAL COLORECTAL CANCER, 2014, 13 (03) : 156 - 163
  • [23] PHASE II STUDY OF IRINOTECAN PLUS CETUXIMAB FOR PRETREATED METASTATIC COLORECTAL CANCER WITH KRAS WILD TYPE
    Shitara, Kohei
    Yokota, Tomoya
    Takahari, Daisuke
    Ura, Takashi
    Inaba, Yoshitaka
    Yamaura, Hidekazu
    Sato, Yozo
    Najima, Mina
    Kawai, Hiroki
    Tajika, Masahiro
    Sawaki, Akira
    Yatabe, Yasushi
    Utsunomiya, Setsuo
    Muro, Kei
    ANNALS OF ONCOLOGY, 2010, 21 : 13 - 13
  • [24] Ganetespib, a Novel Hsp90 Inhibitor in Patients With KRAS Mutated and Wild Type, Refractory Metastatic Colorectal Cancer
    Cercek, Andrea
    Shia, Jinru
    Gollub, Marc
    Chou, Joanne F.
    Capanu, Marinela
    Raasch, Pamela
    Reidy-Lagunes, Diane
    Proia, David A.
    Vakiani, Efsevia
    Solit, David B.
    Saltz, Leonard B.
    CLINICAL COLORECTAL CANCER, 2014, 13 (04) : 207 - 212
  • [25] Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer
    Macarulla, T.
    Cervantes, A.
    Tabernero, J.
    Rosello, S.
    Van Cutsem, E.
    Tejpar, S.
    Prenen, H.
    Martinelli, E.
    Troiani, T.
    Laffranchi, B.
    Jego, V.
    von Richter, O.
    Ciardiello, F.
    BRITISH JOURNAL OF CANCER, 2015, 112 (12) : 1874 - 1881
  • [26] Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer
    T Macarulla
    A Cervantes
    J Tabernero
    S Roselló
    E Van Cutsem
    S Tejpar
    H Prenen
    E Martinelli
    T Troiani
    B Laffranchi
    V Jego
    O von Richter
    F Ciardiello
    British Journal of Cancer, 2015, 112 : 1874 - 1881
  • [27] Lung metastasis as predictor for prognosis in metastatic colorectal cancer with mutated KRAS.
    Boursi, Ben
    Shacham-Shmueli, Einat
    Lawrence, Yaacov Richard
    Yang, Yu-Xiao
    Reiss, Kim Anna
    Golan, Talia
    Mamtani, Raashi
    Halpern, Naama
    Aderka, Dan
    Giantonio, Bruce
    Margalit, Ofer
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [28] Lung Metastasis Predicts Better Prognosis in Metastatic Colorectal Cancer With Mutated KRAS
    Margalit, Ofer
    Shacham-Shmueli, Einat
    Lawrence, Yaacov R.
    Yang, Yu-Xiao
    Reiss, Kim A.
    Golan, Talia
    Mamtani, Raashi
    Halpern, Naama
    Aderka, Dan
    Giantonio, Bruce
    Boursi, Ben
    CLINICAL COLORECTAL CANCER, 2019, 18 (03) : E300 - E307
  • [29] An Unusual Combination: KRAS and BRAF Co-mutated Metastatic Colorectal Cancer
    Epperla N.
    George B.
    Journal of Gastrointestinal Cancer, 2016, 47 (2) : 206 - 209
  • [30] Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines
    Yuki, S.
    Shitara, K.
    Yoshida, M.
    Takahari, D.
    Utsunomiya, S.
    Yokota, T.
    Sato, Y.
    Tajika, M.
    Muro, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
12345